3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
8
Multiple Myeloma
4
Glioma
4
Thyroid Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Interventions
Specimen Handling
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
fludarabine
3
aldesleukin
3
Radiosurgery
3
Oxaliplatin
3
Endoscopic Mucosal Resection
3
Cyclophosphamide
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
Tomography, X-Ray Computed
2
Surveys and Questionnaires
2
Sunitinib
2
Pemetrexed
2
Leucovorin
2
IDRX-42
2
Folfox protocol
2
Endoscopy, Digestive System
2
Biopsy
2
trastuzumab deruxtecan
1
tislelizumab
1
sodium thiosulfate
1
sodium propionate
1
semaglutide
1
s-formylglutathione hydrolase
1
repotrectinib
1
regorafenib
1
plecanatide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
dabrafenib
×
90 days
×
Clear all
No trials found.